News
February 5, 2019

Regenstrief Scientist Says African Americans Have Higher Rate of Alzheimer’s Disease, Quoted in USA Today

Daniel Bateman, M.D., says a number of studies show a higher rate of Alzheimer’s disease in African Americans. He told USA Today there are some hypotheses to explain this.

“There are higher rates of diabetes, hypertension, high cholesterol, heart disease and diabetes in African Americans compared to whites. All of those are risk factors for Alzheimer’s and dementia,” said Dr. Bateman. He points to a 2018 study, which also looked at a number of factors of people who have had a stroke, that found that African Americans had an increased rate for all five types of dementia.

Joanne Pike, vice president of programs for the Alzheimer’s Association in Chicago, says that African Americans are twice as likely to have Alzheimer’s, less likely to receive a diagnosis and more likely to be diagnosed in later stages of the disease. Researchers are looking at many avenues to understand the reasons why.

Regenstrief Institute does a large amount of work in the area of Alzheimer’s and dementia. From testing new care models to decision support and the effects of medication on the brain.  Dr. Bateman’s work is focused on Alzheimer’s disease, specifically innovative approaches to measure and treat behavioral and psychological symptoms of dementia by leveraging technologies. He serves as a co-investigator on the Indiana Alzheimer Disease Center (IADC) Outreach and Recruitment (OR) Core and contributes to the IADC Clinical Core.

Read the USA Today article featuring Dr. Bateman here.

  • Daniel Bateman

Related News

(From left to right) Dr. Brian Dixon, Dr. Sanji De Sylva and Isaac Vetter. Photo credit: Svetlana Efimova

Regenstrief experts advance global dialogue on digital health and interoperability at forum in Dubai

Regenstrief informaticians joined global leaders who shared their expertise at the 8th ZIMAM Digital Health Forum November 5-6, in

Regenstrief researchers join national stage to advance aging and gerontology research

Regenstrief Institute research scientists joined leading experts from across the nation at the Gerontological Society of America (GSA) 2025

illustration of the combination of interventions used in the D3 pragmatic clinical trial

Zero-cost, AI-driven digital detection identifies Alzheimer’s and related dementias without additional clinician time

Few primary care practices are designed for the timely detection of Alzheimer’s disease and related dementias. The limited time